Expert Interview
Discussing the standard of care and the potential of ENTYVIO (vedolizumab) as a maintenance therapy given subcutaneously for ulcerative colitis.
Ticker(s): TAKInstitution: Anderson Hospital
- Gastroenterologist that manages 40 patients a month with NERD and 20 patients a month with ulcerative colitis.
- Familiar with the VISIBLE 1 trial that tested Entyvio as a maintenance therapy given subcutaneously for ulcerative colitis.
- Subspecialities: Biliary Tract Disease, Esophagus Disease, Gastrointestinal Functional & Motility Disorders.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
